The question

NIOX Group's (LSE:NIOX) recent announcements have been about its tender offer and the resulting changes in shareholdings, most recently a notice on 9 November that Artemis Investment Management held just over 5% of the voting rights. Nothing substantive appeared between 12 and 16 November. This article therefore returns to the interim results of 29 September 2026 and looks at a smaller but volatile part of the business: sales to drug developers running clinical trials.

What happened to Clinical-trial sales

Group Revenue for the six months to 30 June 2026 was £24.0m, down from £25.2m. Clinical revenue, from sales to doctors and hospitals, rose 3% to £20.6m, or was broadly unchanged at constant currency; the company said more than 90% of clinical sales are recurring consumables. Clinical-trial revenue, from pharmaceutical companies and contract trial organisations using NIOX devices in studies, fell to £3.4m from £5.2m, a decline of about 35%.

The company gave two reasons. It described the prior-year half as unusually high, so trial activity had normalised. It also said it chose to prioritise available inventory for clinical customers during the changeover to its new NIOX PRO device. In other words, part of the decline was a Supply decision rather than lost demand, although the company did not quantify the split.

Why it mattered for profit

Clinical-trial sales are lumpy, but their fall goes a long way to explaining the profit slippage. Adjusted EBITDA declined to £8.3m from £9.2m, and the Margin to 34.6% from 36.5%. Gross margin improved to 71% because clinical sales carried a higher weighting. Sales and Marketing spending rose to £6.5m from £5.8m as the US field sales team was fully deployed in March, while administrative costs fell. Profit before tax was £6.0m, against £5.9m.

Better visibility, in principle

During the half NIOX (LSE:NIOX) signed a master services agreement with its largest contract trial customer, which the company said improves visibility of future Clinical-trial revenue. NIOX describes its devices as the choice of leading contract trial organisations for respiratory studies, so Demand tends to follow the number and timing of those trials. It also expects clinical trial activity to increase in the second half. A ten-year exclusive sensor supply agreement was signed, which supports both product lines. The company did not disclose the agreement's financial terms.

What the second half requires

The board said it expected the second half to be ahead of the first and full-year revenue and adjusted EBITDA to be in line with consensus, without quoting the consensus figures. Matching last year's £48.7m revenue would require about £24.7m in the second half; the company has not set that as a target. Delivery depends on the NIOX PRO rollout, higher Japanese pricing from 1 June and a recovery in clinical-trial orders. The company also expects clinical demand deferred by the timing of NIOX PRO approvals to be fulfilled in the second half.

Cash is tighter after the £12.5m tender at 80p completed in October. The company guided to about £9.0m of cash at 31 December 2026, citing elevated inventory ahead of further NIOX PRO approvals. That leaves less room if clinical-trial demand stays subdued.

Factors to watch and next steps

Clinical-trial revenue depends on the timing of third-party trials, which NIOX (LSE:NIOX) does not control. China remains a drag on clinical sales because of reimbursement cuts and low-cost competition. US and Japanese regulatory submissions for NIOX PRO are still in progress. Development of MyNO, a home-use device, adds longer-term cost. Following the tender, 405,241,313 shares are in issue; the directors and Harwood Capital, a substantial shareholder, all tendered at least their basic entitlements, with Harwood selling 4,336,495 shares.